Spinocerebellar Ataxia – Executive Insights – Spinocerebellar Ataxia | Executive Insights | US/EU5/Portugal/China
Spinocerebellar ataxia (SCA) is a heterogeneous group of rare neurodegenerative progressive disorders that primarily affects the cerebellum, and, in some cases, the spinal cord, resulting in the loss of balance and movement coordination. SCA subtypes 1, 2, and 3 are among the most common subtypes. Given the rarity of the condition and the symptomatic similarity to other progressive neurological disorders, reaching a definitive diagnosis of SCA is often a lengthy process. No therapies are approved to treat SCA; treatment consists entirely of symptomatic therapies used off-label, often together with supportive nonpharmacological approaches (e.g., physical therapy). As a result, the burden on patients and caregivers is high. Thus, a critical need exists for treatment options—both disease-modifying and symptomatic therapies—that can address SCA symptoms better than current off-label options. Given the debilitating nature of the disease and the lack of approved therapies, the market is primed to accept any safe, even modestly effective treatment at premium pricing.
QUESTIONS ANSWERED
- What is the diagnosed prevalence of SCA1, 2, and 3, and how are patients treated today in the different geographies under study?
- What are the key areas of unmet need and opportunity in managing SCA?
- What is the state of the drug development pipeline for SCA? What is the potential impact of new launches, and how will these therapies affect future opportunity in the treatment of SCA?
- What are the key drivers and limiters of the market today and in the future?
PRODUCT DESCRIPTION
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
GEOGRAPHY: United States, EU5, Portugal, China
PRIMARY RESEARCH: 8 KOL interviews in June-July 2021
KEY COMPANIES COVERED: Biohaven Pharmaceuticals, Steminent, Sclnow Biotechnology, Seelos Therapeutics
KEY DRUGS COVERED: Troriluzole, Stemchymal, SCLnow -19#, trehalose
Kanika Ujla, M.S., is an analyst on the Infectious, Niche, and Rare Diseases team at Clarivate. She conducts primary and secondary research in a range of antibacterial and antiviral indications, as well as numerous niche and rare diseases. She has experience in R&D, consulting, and business research with healthcare and life science companies. She obtained her master’s degree in biotechnology from the University of Jammu and her bachelor’s degree in biotechnology from Chaudhary Charan Singh University.